The CADTH Scientific Advice Program is a voluntary, non-binding, and confidential fee-for-service consultation. Through this Program, pharmaceutical companies are provided with advice on their early drug development plans from a Canadian health technology assessment perspective.
Health Canada and CADTH Launch New Initiative to Provide Early Parallel Scientific Advice
CADTH is pleased to announce a new collaboration with Health Canada and the Institut national d'excellence en santé et services sociaux (INESSS) in support of Health Canada’s Regulatory Reviews of Drugs and Devices initiative. Pharmaceutical companies can now receive early parallel scientific advice from CADTH and Health Canada, with INESSS initially participating in an observer role. You can read more about this important new opportunity on the Health Canada website. Pharmaceutical companies wishing to participate in the early parallel scientific advice initiative from CADTH and Health Canada should contact CADTH Scientific Advice at email@example.com.
Published : March 1, 2019